Phase 2 N=399 N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
Radiocontrast Nephropathy
Primary: Number of Participants With Contrast-induced Nephropathy — 14; 12 Participants — p=>0.5
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=88 Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Number of Phase I Patients Receiving 60mg or 80mg BKM120 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 3 Participants
Phase 2 N=51 Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements
Edematous · Synovitis · Foreign Body Reaction
Primary: Pain Visual Analog Scale (VAS) — 57; 46.8; 39.7; 39.1 units on a scale — p=0.0063
Phase 2 N=227 Investigating the Effect of Vortioxetine in Adult ADHD Patients
Attention Deficit Hyperactivity Disorder
Primary: Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score — -12.4; -12.8; -11.6; -4.1 units on a scale — p=0.9723
Phase 2 N=13 Early FMT for C.Difficile
Clostridium Difficile
Primary: Clinical Remission Rates — 3; 2 Participants
Phase 2 N=62 Novel Smoking Cessation Drug for Schizophrenia
Smoking Cessation
Primary: Quit Status — 0.46; 0.54 days abstinent
Phase 2 N=224 A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
Breast Cancer · Hormone Receptor Positive Tumor · Early-Stage Breast Carcinoma
Primary: Percent Change From Baseline to 2 Weeks in Ki67 Expression — -92.86; -90.52; -62.78 Percent Change — p=<0.001
Phase 2 N=17 A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Carcinoma, Non-small-cell Lung
Primary: Number of Participants That Experience Progression-free Survival. — 1 Participants
Phase 2 N=13 Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH
Primary: Percent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169 — -85.952; -84.736 percent change
Phase 2 N=40 SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis
Rhinitis
Primary: Mean Total Symptom Score (TSS) Elicited by a 1 Hour (h) Cold Dry Air (CDA) Challenge, 1 h and 24 h on Day 14 to Compare the Effect of 14 Day Repeat Dosing of Intranasal…
Phase 2 N=176 Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis
Psoriasis
Primary: Psoriasis Area Severity Index (PASI)75 Success at Visit 6 — 4; 7; 4; 5 Participants — p=0.884
Phase 2 N=33 Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
Osteoarthritis of the Knee · Type 2 Diabetes Mellitus
Primary: Change From Baseline for Average Blood Glucose (mg/dL) — 14.66; 33.88 mg/dL — p=0.0452
Phase 2 N=62 Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
Asthma
Primary: Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1) — 0.202; 0.477; 0.524; 0.573 Liters — p=<0.0001
Phase 2 N=63 Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate of Bortezomib and Rituximab (VR) in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (WM) — 30 Participants
Phase 2 N=47 Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
Tuberous Sclerosis Complex
Primary: Evaluation of the Safety of RAD001 on Neurocognition in Patients With TSC Compared With Placebo in Patients With TSC. — 325; 147 Adverse Events